PRGS ranging from 1 to 4 in 13 patients with peritoneal metastasis from pancreatic cancer who underwent at least two PIPAC treatments
| Patient 1 | Patient 2 | Patient 3 | Patient 4* | Patient 5 | Patient 7* | Patient 10* | Patient 11 | Patient 12 | |
| PRGS before PIPAC 1 (highest/mean) | 3/2.25 | 3/2 | 3/2.25 | 4/2.75 | 3/3 | 1/1 | 3/2.25 | 2/1.33 | 1/1 |
| PRGS before PIPAC 3 (or 2*) (highest/mean) | 2/1.75 | 3/1.75 | 3/1.5 | 3/2.25 | 3/2 | 1/1 | 3/2 | 1/1 | 1/1 |
| Histological response | + | + | + | + | + | U | + | + | U |
| Patient 13* | Patient 14* | Patient 15* | Patient 16* | |
| PRGS before PIPAC 1 (highest/mean) | 1/1 | 1/1 | 3/2 | 3/3 |
| PRGS before PIPAC 3 (or 2*) (highest/mean) | 1/1 | 1/1 | 3/2.33 | 2/2 |
| Histological response | U | U | – | + |
– indicates histological progression (according to mean PRGS); + indicates histological regression (according to mean PRGS).
*Did only undergo PIPAC twice, data from PIPAC 2 instead of PIPAC 3.
PIPAC, Pressurised IntraPeritoneal Aerosol Chemotherapy; PRGS, Peritoneal Regression Grading Score; U, unchanged mean PRGS.